SEC Form 4 · accession 0001209191-17-031376

Ovid Therapeutics Inc. · OVID

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — CEO · Director · 10% Owner

Period of report

May 10, 2017

Accepted (ET)

May 10, 2017 · 5:16 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001636651

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	May 10, 2017	C	400,150	—	A	4,586,195	D
Common Stock^F1,F2	May 10, 2017	C	35,461	—	A	35,461	I	See Footnote
Common Stock^F3	holding	—	—		—	465,116	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F1	—	May 10, 2017	C	400,150	D	—	—	Common Stock	400,150	0	D
Series B Preferred Stock^F2,F1	—	May 10, 2017	C	35,461	D	—	—	Common Stock	35,461	0	I

F1The Series A Preferred Stock and Series B Preferred Stock converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering, on a one-for-one basis and had no expiration date.
F2The reportable securities are owned directly by Divo Holdings, LLC ("Divo"). The Reporting Person's spouse in the manager of Divo. The Reporting Person disclaims beneficial ownership of these shares and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose.
F3The reportable securities are owned directly by DSL-EAL Holdings LLC (the "LLC"). The Reporting Person is the manager of the LLC. The Reporting Person may be deemed to share voting and investment powers for the shares held by the LLC. The Reporting Person disclaims beneficial ownership of the shares held by the LLC and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose, except to the extent of any pecuniary interest therein.